Ultimately, the interview underscores a critical transition period for the industry. While tariffs present a unique hurdle ...

In a 2026 industry outlook interview, Raj Puri explains balancing speed with the financial and regulatory risks of accelerated drug launches via alignment. Raj Puri, chief commercial officer at ...

The upgrade follows recent developments at Sentynl Therapeutics, a subsidiary of Zydus Lifesciences, which secured U.S. FDA ...

Both products can be used in the UK to provide protection against RSV disease in certain settings. Abrysvo was cleared for ...

The Pune-based company is employing a user-first approach, going beyond healthcare providers, as weight-loss drugs continue ...

Americans pay about three times what other wealthy nations do for branded prescription drugs. For years, policymakers have tried to fix this by cutting U.S. drug prices directly. President Trump has ...

When it comes to developing new cancer treatments, too often teams are focused on finding the treatment that most effectively kills tumours. But that’s only part of the goal, argues Immuneering CEO ...

New Hampshire Republican Senate candidate John E. Sununu tried to hide his ties to big pharma in a recent interview on the radio program New Hampshire Today. Sununu, a former one-term senator who lost ...

While the president's ire can return on a whim, the prospect of an Oval Office dressing down appears, for the moment, off the ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Novo Nordisk's shares tumbled as much as 20% ...

The next major drugmaker interested in what Repertoire has to offer is Eli Lilly, which has thrown down $85 million upfront and floated up to $1.84 billion more in biobucks to collaborate on potential ...

Groningen’s LIFE Cooperative wants to align its plans with the EU’s industrial strategy to funnel investments toward biotech, ...